PriceTargets.com logo

Mallinckrodt - MNK Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.12 As of 11/14/2023 01:00 AM ET
+0 (0.00%)
Get New Mallinckrodt Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Mallinckrodt in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.12.

This chart shows the closing price for MNK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Mallinckrodt. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/15/2020Raymond JamesReiterated RatingHold
9/14/2020Leerink PartnersLower TargetMarket Perform$2.00 ➝ $1.50
8/5/2020BarclaysReiterated RatingHold
8/5/2020BMO Capital MarketsLower TargetMarket Perform$4.00 ➝ $2.00
8/4/2020Piper SandlerDowngradeNeutral ➝ Underweight
5/19/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
5/6/2020Leerink PartnersBoost TargetMarket Perform$2.00 ➝ $3.00
4/24/2020CitigroupInitiated CoverageSell
4/2/2020BarclaysLower TargetEqual Weight$5.00 ➝ $3.00
4/1/2020CfraLower TargetHold$6.00 ➝ $4.00
2/26/2020Bank of AmericaBoost TargetUnderperform$3.00
1/22/2020Wells Fargo & CompanyReiterated RatingHold
(Data available from 12/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Mallinckrodt logo
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.
Read More

Today's Range

Now: $0.12
Low: $0.07
High: $0.13

50 Day Range

MA: $0.34
Low: $0.14
High: $0.75

52 Week Range

Now: $0.12
Low: $0.75
High: $6.42

Volume

39,227 shs

Average Volume

2,623,583 shs

Market Capitalization

$1.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Mallinckrodt?

The following sell-side analysts have issued reports on Mallinckrodt in the last twelve months:
View the latest analyst ratings for MNK.

What is the current price target for Mallinckrodt?

0 Wall Street analysts have set twelve-month price targets for Mallinckrodt in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mallinckrodt in the next year.
View the latest price targets for MNK.

What is the current consensus analyst rating for Mallinckrodt?

Mallinckrodt currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MNK.

What other companies compete with Mallinckrodt?

Other companies that are similar to Mallinckrodt include Xenetic Biosciences, CNS Pharmaceuticals, Galecto, Alzamend Neuro and Quantum Biopharma. Learn More about companies similar to Mallinckrodt.

How do I contact Mallinckrodt's investor relations team?

Mallinckrodt's physical mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company's listed phone number is (531) 696-0000 and its investor relations email address is [email protected]. The official website for Mallinckrodt is www.mallinckrodt.com. Learn More about contacing Mallinckrodt investor relations.